학술논문

Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial
Document Type
Article
Source
In: Vaccine. (Vaccine, 2 April 2024, 42(9):2438-2447)
Subject
Language
English
ISSN
18732518
0264410X